# Jordan Lerner-Ellis

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8945518/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 44 papers | 1,415 citations | 623734 14 h-index | 345221 36 g-index |
| 46 all docs | 46 docs citations | 46 times ranked | 3227 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nature Genetics, 2015, 47, 257-262. | 21.4 | 306 |
| 2 | Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer. Gastroenterology, 2015, 148, 556-564. | 1.3 | 256 |
| 3 | Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. European Journal of Cancer, 2014, 50, 987-996. | 2.8 | 180 |
| 4 | Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 2014, 120, 3932-3939. | 4.1 | 114 |
| 5 | Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. Modern Pathology, 2017, 30, 1748-1759. | 5.5 | 72 |
| 6 | Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Expert Review of Anticancer Therapy, 2015, 15, 1315-1326. | 2.4 | 42 |
| 7 | The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results. European Journal of Human Genetics, 2018, 26, 984-995. | 2.8 | 42 |
| 8 | Variant classification changes over time in BRCA1 and BRCA2. Genetics in Medicine, 2019, 21, 2248-2254. | 2.4 | 37 |
| 9 | Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial. Genetics in Medicine, 2020, 22, 727-735. | 2.4 | 34 |
| 10 | Canadian Open Genetics Repository (COGR): a unified clinical genomics database as a community resource for standardising and sharing genetic interpretations. Journal of Medical Genetics, 2015, 52, 438-445. | 3.2 | 27 |
| 11 | Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR). Genetics in Medicine, 2018, 20, 294-302. | 2.4 | 27 |
| 12 | Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. British Journal of Cancer, 2019, 120, 398-403. | 6.4 | 25 |
| 13 | Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial. BMJ Open, 2022, 8, e021876. | 1.9 | 22 |
| 14 | The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care. Genetics in Medicine, 2021, 23, 1086-1094. | 2.4 | 18 |
| 15 | Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. Cancer, 2020, 126, 4886-4894. | 4.1 | 15 |
| 16 | Quality of life drives patientsâ€™ preferences for secondary findings from genomic sequencing. European Journal of Human Genetics, 2020, 28, 1178-1186. | 2.8 | 14 |
| 17 | Exome and genome sequencing in adults with undiagnosed disease: a prospective cohort study. Journal of Medical Genetics, 2021, 58, 275-283. | 3.2 | 14 |
| 18 | Data sharing to improve concordance in variant interpretation across laboratories: results from the Canadian Open Genetics Repository. Journal of Medical Genetics, 2022, 59, 571-578. | 3.2 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Beyond medically actionable results: an analytical pipeline for decreasing the burden of returning all clinically significant secondary findings. Human Genetics, 2021, 140, 493-504. | 3.8 | 13 |
| 20 | Genetic testing for Lynch syndrome in the province of Ontario. Cancer, 2016, 122, 1672-1679. | 4.1 | 12 |
| 21 | Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. Cancers, 2020, 12, 3468. | 3.7 | 12 |
| 22 | An Integrative DNA Sequencing and Methylation Panel to Assess Mismatch Repair Deficiency. Journal of Molecular Diagnostics, 2021, 23, 242-252. | 2.8 | 12 |
| 23 | Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. BMJ Open, 2019, 9, e031092. | 1.9 | 10 |
| 24 | Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel. Journal of Medical Genetics, 2020, 57, 380-384. | 3.2 | 10 |
| 25 | Widening the lens of actionability: A qualitative study of primary care providersâ€™ views and experiences of managing secondary genomic findings. European Journal of Human Genetics, 2022, 30, 595-603. | 2.8 | 10 |
| 26 | Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery. BMJ Open, 2022, 12, e060899. | 1.9 | 10 |
| 27 | Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. Gynecologic Oncology, 2021, 161, 221-227. | 1.4 | 9 |
| 28 | A high frequency of PALB2 mutations in Jamaican patients with breast cancer. Breast Cancer Research and Treatment, 2017, 162, 591-596. | 2.5 | 8 |
| 29 | Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario. Journal of Cancer Research and Clinical Oncology, 2021, 147, 871-879. | 2.5 | 7 |
| 30 | Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. Cancer, 2021, 127, 3082-3091. | 4.1 | 6 |
| 31 | Implementation of serological and molecular tools to inform COVID-19 patient management: protocol for the GENCOV prospective cohort study. BMJ Open, 2021, 11, e052842. | 1.9 | 6 |
| 32 | Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers. International Journal of Gynecological Cancer, 2020, 30, 1951-1958. | 2.5 | 5 |
| 33 | Principles of molecular testing for hereditary cancer. Genes Chromosomes and Cancer, 2022, 61, 356-381. | 2.8 | 5 |
| 34 | Challenges and practical solutions for managing secondary genomic findings in primary care. European Journal of Medical Genetics, 2022, 65, 104384. | 1.3 | 4 |
| 35 | Real-world health services utilisation and outcomes afterBRCA1andBRCA2testing in Ontario, Canada: the What Comes Next Cohort Study protocol. BMJ Open, 2018, 8, e025317. | 1.9 | 3 |
| 36 | Patient and public preferences for being recontacted with updated genomic results: a mixed methods study. Human Genetics, 2021, 140, 1695-1708. | 3.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Reply to â€˜Mutations in RECQL are not associated with breast cancer risk in an Australian populationâ€™. Nature Genetics, 2018, 50, 1348-1349. | 21.4 | 2 |
| 38 | PALB2 mutations in high-risk women with breast or ovarian cancer.. Journal of Clinical Oncology, 2017, 35, 1527-1527. | 1.6 | 2 |
| 39 | Identification of a novel MSH6 germline variant in a family with multiple gastro-intestinal malignancies by next generation sequencing. Familial Cancer, 2015, 14, 69-75. | 1.9 | 1 |
| 40 | Outcomes associated with rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis.. Journal of Clinical Oncology, 2019, 37, 1577-1577. | 1.6 | 1 |
| 41 | A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings. Human Genetics, 2022, 141, 1875-1885. | 3.8 | 1 |
| 42 | Performance characteristics of brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed ovarian cancers.. Journal of Clinical Oncology, 2021, 39, e22525-e22525. | 1.6 | 0 |
| 43 | Molecular-based classification algorithm for endometrial carcinoma to categorize ovarian endometrioid carcinoma into prognostically significant groups.. Journal of Clinical Oncology, 2017, 35, e17081-e17081. | 1.6 | 0 |
| 44 | Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers. International Journal of Gynecological Cancer, 2022, , ijgc-2021-003082. | 2.5 | 0 |